Vaccitech is a clinical stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases. The company’s proprietary technology platform, comprising Chimpanzee Adenovirus (prime) and MVA (boost) is exceptional at inducing, boosting and maintaining CD8+ and CD4+ T cells, as well as antibodies.

Thomas G. Evans
Chief Scientific Officer & Board Director
Meg Marshall
Chief Medical Officer
Chris Ellis
Chief Operating Officer
Graham Griffiths
Chief Business Officer
Georgy Egorov
Chief Financial Officer
Adrian Hill
Co-Founder & Scientific Advisor
Sarah Gilbert

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.